Related references
Note: Only part of the references are listed.Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis
Veronika Dill et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas
Susanne A. Gatz et al.
FRONTIERS IN ONCOLOGY (2019)
FBXW7: a critical tumor suppressor of human cancers
Chien-Hung Yeh et al.
MOLECULAR CANCER (2018)
Proteasome mediated degradation of CDC25C and Cyclin B1 in Demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrest
Neetika Lal et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2018)
Sodium Fluoride Arrests Renal G2/M Phase Cell-Cycle Progression by Activating ATM-Chk2-P53/Cdc25C Signaling Pathway in Mice
Qin Luo et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis
Zheng Fu et al.
CANCERS (2017)
Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma
Cliff I. Oduor et al.
BMC CANCER (2017)
C-MYC and Its Main Ubiquitin Ligase, FBXW7, Influence Cell Proliferation and Prognosis in Adult T-cell Leukemia/Lymphoma
Yasuhito Mihashi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors
Hiroshi Nokihara et al.
INVESTIGATIONAL NEW DRUGS (2016)
Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration
Ana Carolina dos Santos Ferreira et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor
J. Van den Bossche et al.
MEDICINAL RESEARCH REVIEWS (2016)
Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival
Daibiao Xiao et al.
MOLECULAR CELL (2016)
Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis
Hajime Otsu et al.
ONCOLOGY (2016)
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia
Yukio Kobayashi et al.
CANCER SCIENCE (2015)
Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression
Fat-Moon Suk et al.
ONCOTARGET (2015)
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
Gemma L. Kelly et al.
GENES & DEVELOPMENT (2014)
Plk1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic State
Zhiguo Li et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Orphan drug designation for pracinostat, volasertib and alvocidib in AML
Prithviraj Bose et al.
LEUKEMIA RESEARCH (2014)
Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification
German Ott et al.
BLOOD (2013)
Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
Sandrine Sander et al.
CANCER CELL (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz et al.
NATURE (2012)
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas
Aadra P. Bhatt et al.
BLOOD (2010)
Expression of PLK1 and survivin in non-Hodgkin's lymphoma treated with CHOP
Lin Liu et al.
ACTA PHARMACOLOGICA SINICA (2008)
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression
Jian-Hua Mao et al.
SCIENCE (2008)
Plk1 promotes nuclear translocation of human Cdc25C during prophase
F Toyoshima-Morimoto et al.
EMBO REPORTS (2002)
Share Paper
